申请人:KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
公开号:EP0514942A1
公开(公告)日:1992-11-25
The present invention relates to novel benzopyran derivatives of formula(I) which have exellent effectiveness in the treatment of asthma as well as hypertension. The present invention also relates to processes for preparing such compounds and to pharmaceutical compositions containing such compounds as an effective ingredient:
wherein:
R₁ is-CN, -NO₂, -OCX₁X₂X₃, -NH₂, -NHSO₂RA,
-SO₂RC or -SO₂NRCRD wherein X₁, X₂ and X₃ are, each independently, F, Cl or H, except for that X₁, X₂ and X₃ may not be hydrogen atom simulaneously; RA and RB are, each independently, a hydrogen atom, or a C₁₋₆ alkyl group or an optionally substituted phenyl group with a halogen atom, or a straight or branched C₁₋₃ alkyl group; and RC and RD are, each independently, a hydrogen atom or a C₁₋₆ alkyl group or an optionally substituted phenyl group with a halogen atom, or a straight or branched C₁₋₃ alkyl group;
R₂ isa C₁₋₄ straight or branched alkyl group;
R₃ isa C₁₋₄ straight or branched alkyl group,
wherein RG and RH are, each independently, a C₁₋₆ alkyl group or optionally substituted phenyl group with a halogen atom, or a straight or branched C₁₋₃ alkyl group, A and B are, each independently, S or O; and Z is a C₁₋₃ straight or branched alkyl group;
X isN or N → O, provided, however, when X is in 2-position, R₃ is
and
Y isa hydrogen or halogen atom, or an amino, hydroxy, a lower alkoxy or lower alkyl group.
本发明涉及新型的式(I)苯并吡喃衍生物,该衍生物在治疗哮喘和高血压方面具有卓越的疗效。本发明还涉及制备此类化合物的工艺以及含有此类化合物作为有效成分的药物组合物:
其中
R₁是-CN、-NO₂、-OCX₁X₂X₃、-NH₂、-NHSO₂RA、
-其中 X₁、X₂ 和 X₃ 各自独立地为 F、Cl 或 H,但 X₁、X₂ 和 X₃ 不得同时为氢原子;RA 和 RB 分别独立地为氢原子、C₁₋₆ 烷基或带有卤素原子的任选取代苯基、直链或支链 C₁₋₃ 烷基;RC 和 RD 各自独立地为氢原子或 C₁₋₆ 烷基或带有卤素原子的任选取代的苯基或直链或支链 C₁₋₃ 烷基;
R₂ 是 C₁₋₄ 直链或支链烷基;
R₃ 是 C₁₋₄ 直链或支链烷基、
其中 RG 和 RH 各自独立地为 C₁₋₆烷基或被卤原子任选取代的苯基,或直链或支链 C₁₋₃烷基,A 和 B 各自独立地为 S 或 O;以及 Z 为 C₁₋₃直链或支链烷基;
X 是 N 或 N → O,但当 X 位于 2 位时,R₃ 是
和
Y 是氢原子或卤素原子,或氨基、羟基、低级烷氧基或低级烷基。